Bladder cancer: open trials in South Korea

34 open trials have a site in South Korea. Registry data; only the trial team decides who can take part.

NCT07206225
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Trial Treatment · Phase 1 · Pfizer
Samsung Medical Center, Seoul · Seoul National University Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul
Registry updated 2026-11-05
NCT05614739
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Trial Treatment · Phase 1 · Eli Lilly and Company
Samsung Medical Center, Seoul · Severance Hospital, Yonsei University Health System, Seoul · Asan Medical Center, Seoul · Seoul National University Hospital, Seoul
Registry updated 2026-11-04
NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Trial Treatment · Phase 1 · Eli Lilly and Company
Asan Medical Center, Seoul
Registry updated 2026-11-04
NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Trial Treatment · Phase 2 · Jazz Pharmaceuticals
Samsung Medical Center, Gangnam-Gu · Korea University Guro Hospital, Guro-gu · Chonnam National University Hwasun Hospital, Hwasun-Eup · Seoul National University Hospital, Jongno-gu · Severance Hospital, Seodaemun-gu · Asan Medical Center, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Seoul National University Bundang Hospital, Seoul · The Catholic University of Korea St. Vincent's Hospital, Suwon · National Cancer Center Suwon, Suwon
Registry updated 2026-11-04
NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 2 · Bayer
Seoul National University Hospital | Oncology, Jongno -Gu · Asan Medical Center - Oncology, Seoul · Severance Hospital | Oncology, Seoul · Samsung Medical Center | Oncology, Seoul
Registry updated 2026-11-04
NCT06319820
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Chungbuk National University Hospital, Chuncheon · National Cancer Center, Gyeongin · Chonnam National University Hwasun Hospital, Sangam-dong · Seoul National University Hospital, Seoul · The Catholic University of Korea Seoul St Marys Hospital, Seoul · Samsung Medical Center, Seoul
Registry updated 2026-11-03
NCT06919965
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Chungbuk National University Hospital, Cheongju-si · Samsung Medical Center, Ganggu · Seoul National University Bundang Hospital, Seongnam · Severance Hospital, Yonsei University Health System, Seoul · Seoul National University Hospital, Seoul
Registry updated 2026-11-03
NCT07475806
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Trial Treatment · Phase 2 · Astellas Pharma Global Development, Inc.
Gyeonggi-do · Hwasun · Seongnam-si · Seoul · Seoul · Seoul · Seoul · Seoul
Registry updated 2026-11-02
NCT06510374
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Trial Treatment · Phase 3 · Ferring Pharmaceuticals
National Cancer Center, Goyang-si · Chonnam National University Hwasun Hospital (CNUHH), Hwasun · Samsung Medical Center, Seoul · Severance Hospital, Yonsei University Health System, Seoul · Seoul National University Hospital, Seoul · Korea University Anam Hospital, Seoul · Asan Medical Center, Seoul · Pusan National University Yangsan Hospital, Yangsan
Registry updated 2026-10-30
NCT06545955
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Trial Treatment · Phase 3 · Ferring Pharmaceuticals
Chonnam National University Hwasun Hospital (CNUHH) Organisa, Hwasun · Korea University Anam Hospital, Seoul · Samsung Medical Center, Seoul · Seoul National University Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul · Pusan National University Yangsan Hospital, Yangsan
Registry updated 2026-10-30
NCT07566156
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Trial Treatment · Phase 3 · Astellas Pharma Global Development, Inc.
Daegu · Seongnam-si · Seoul · Seoul
Registry updated 2026-10-28
NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Trial Treatment · Phase 2 · Daiichi Sankyo
Kyungpook National University Chilgok Hospital, Daegu · National Cancer Center, Gyeonggi-do · Seoul National University Bundang Hospital, Seongnam · CHA Bundang Medical Center, CHA University, Seongnam · Seoul National University Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul · Samsung Medical Center, Seoul · Asan Medical Center, Seoul
Registry updated 2026-10-26
NCT06011954
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Research · Astellas Pharma Korea, Inc.
Busan · Busan · Busan · Busan · Daegu · Daejeon · Goyang-si · Incheon · Jeollanam-do · Jeonju · Seoul · Seoul · Seoul · Seoul · Seoul · Seoul · Suwon · Suwon
Registry updated 2026-10-20
NCT04977453
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Trial Treatment · Phase 1/2 · GI Innovation, Inc.
Chungnam National University Hospital, Daejeon · Ewha Womans University Mokdong Hospital, Seoul · Seoul National University Bundang Hospital, Seoul · Yonsei University Health System, Severance Hospital, Seoul · Asan Medical Center, Seoul · Korea University Anam Hospital, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Samsung Medical Center, Seoul · The Catholic University of Korea St. Vincent's Hospital, Suwon
Registry updated 2026-10-19
NCT07218380
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Trial Treatment · Phase 3 · Eli Lilly and Company
National Cancer Center, Goyang-si · Chungnam national university hospital, Junggu · Gachon University Gil Medical Center, Namdong-gu · Seoul National University Bundang Hospital, Seongnam · Samsung Medical Center, Seoul · Seoul National University Hospital, Seoul · Ewha Womans University Mokdong Hospital, Seoul · The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul · Asan Medical Center, Seoul · Severance Hospital, Yonsei University Health System, Seoul
Registry updated 2026-10-07
NCT07232602
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Severance Hospital, Yonsei University Health System ( Site 5903), Seoul · Asan Medical Center ( Site 5901), Seoul · Samsung Medical Center ( Site 5902), Seoul
Registry updated 2026-10-02
NCT05562830
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Samsung Medical Center ( Site 1902), Seoul · Asan Medical Center ( Site 1901), Seoul · Severance Hospital, Yonsei University Health System ( Site 1903), Seoul
Registry updated 2026-09-28
NCT06253871
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Trial Treatment · Phase 1 · Iambic Therapeutics, Inc
Asan Medical Center, Seoul · Severance Hospital Yonsei Cancer Center, Seoul · Seoul National University Hospital, Seoul · Samsung Medical Center, Seoul
Registry updated 2026-09-09
NCT06644755
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Trial Treatment · Phase 1 · Daiichi Sankyo
Seoul National University Hospital, Seoul
Registry updated 2026-09-04
NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Trial Treatment · Phase 1/2 · Novartis Pharmaceuticals
Keimyung University - Dongsan Medical Center, Daegu · National Cancer Center, Goyang-si · Gachon University Gil Medical Center, Incheon · Seoul National University Hospital, Seoul · Asan Medical Center, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Gangnam Severance Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul
Registry updated 2026-08-19
NCT04752722
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Trial Treatment · Phase 1/2 · enGene, Inc.
Chonnam National University Hwasun Hospital, Hwasun · Seoul National University Bundang Hospital, Seongnam · Severance Hospital, Yonsei University Health System, Seoul · The Catholic University of Korea, Soul St. Mary's Hospital, Seoul · Seoul National University Hospital, Seoul
Registry updated 2026-08-07
NCT04198766
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Trial Treatment · Phase 1/2 · Inhibrx Biosciences, Inc
The Catholic University of Korea St. Vincent's Hospital, Gyeonggi-do · Asan Medical Center, Seoul · The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul · Severance Hospital, Yonsei University Health System, Seoul
Registry updated 2026-07-29
NCT05503797
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Trial Treatment · Phase 2 · Fore Biotherapeutics
Chonnam National University Hwasun Hospital, Hwasun · Dong-A University Hospital, Pusan · Severance hospital, Seoul · Seoul National University Hospital, Seoul · Catholic University of Korea Saint Vincent's Hospital, Suwon · Seoul National University Hospital, Suwon
Registry updated 2026-07-27
NCT07720284
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Trial Treatment · Phase 3 · AstraZeneca
Seoul
Registry updated 2026-07-22
NCT04389632
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Trial Treatment · Phase 1 · Seagen, a wholly owned subsidiary of Pfizer
Chungbuk National University Hospital, Cheongju-si · National Cancer Center, Goyang-si · Korea University Guro Hospital, Seoul · The Catholic University of Korea, Seoul · Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul · Severance Hospital, Yonsei University Health System, Seoul
Registry updated 2026-07-06

All Bladder cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error